InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
surf1944 Free
08/13/08 1:29 PM
profile icon
surf1944 Free
08/07/08 8:06 AM
profile icon
surf1944 Free
06/24/08 7:57 AM
profile icon
surf1944 Free
06/16/08 9:31 AM
profile icon
surf1944 Free
06/02/08 8:14 AM
profile icon
surf1944 Free
05/15/08 7:47 AM
profile icon
surf1944 Free
05/07/08 10:46 AM
profile icon
surf1944 Free
02/25/08 8:51 AM
profile icon
surf1944 Free
02/07/08 12:04 PM
profile icon
grandpatb Free
11/15/07 7:02 AM
profile icon
surf1944 Free
11/15/07 6:55 AM
profile icon
surf1944 Free
11/07/07 8:57 PM
profile icon
surf1944 Free
11/07/07 10:39 AM
profile icon
surf1944 Free
11/06/07 9:32 AM
profile icon
surf1944 Free
11/06/07 7:35 AM
profile icon
surf1944 Free
10/31/07 4:19 PM
profile icon
mlkrborn Free
10/31/07 2:49 PM
profile icon
mlkrborn Free
10/31/07 2:28 PM
profile icon
RockRat Free
10/31/07 1:15 PM
profile icon
surf1944 Free
10/31/07 12:22 PM
profile icon
surf1944 Free
10/31/07 10:21 AM
profile icon
cosmoworld7 Free
10/31/07 10:16 AM
profile icon
surf1944 Free
10/31/07 10:00 AM
profile icon
surf1944 Free
10/31/07 9:45 AM

GPC Biotech AG (GPCB) RSS Feed

Followers
2
Posters
5
Posts (Today)
0
Posts (Total)
26
Created
10/31/07
Type
Free
Moderators
http://www.gpc-biotech.com/en/index.html http://finance.yahoo.com/q/ks?s=GPCB GPC Biotech AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of anticancer drugs in Germany. The company also develops genomics and proteomics technologies that comprises gene expression analysis, protein-protein interaction analysis, and bioinformatic tools, as well as provides related services. It focuses on oncology, immunology, and microbiology. The company's lead product candidate includes satraplatin, a platinum-based compound for chemotherapy treatment in hormone-refractory prostate cancer. It also develops 1D09C3, a monoclonal antibody, which is in Phase I clinical trial for the treatment of lymphoid cancers, as well as has ongoing drug development and discovery programs that focuses on kinase inhibitors. The company has an agreement with ALTANA Pharma to license its proprietary drug-protein interaction technology, LeadCode. GPC Biotech AG was founded in 1997 and is headquartered in Munich, Germany.
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
GPCB Latest News
  • No Recent News Available for this company!
New Post